Combining CD47 blockade with trastuzumab eliminates HER2-positive breast cancer cells and overcomes trastuzumab tolerance.
Upton R, Banuelos A, Feng D, Biswas T, Kao K, McKenna K, Willingham S, Ho PY, Rosental B, Tal MC, Raveh T, Volkmer JP, Pegram MD, Weissman IL.
Upton R, et al. Among authors: biswas t.
Proc Natl Acad Sci U S A. 2021 Jul 20;118(29):e2026849118. doi: 10.1073/pnas.2026849118.
Proc Natl Acad Sci U S A. 2021.
PMID: 34257155
Free PMC article.